Abstract library

110 results for "post-PRRT".
#2013 Optimizing Reconstruction Algorithm to Improve Quality of Post-PRRT Yittrium-90 PET Scan
Introduction: 90Y is commonly used in PRRT for NET. It has no gamma photon in its emission that significantly limits post-therapy imaging and dosimetry. Other than Bremsstrahlung imaging which bears hereditary drawbacks of poor resolution, PET scan has been used for post-PRRT imaging. However, in daily clinical practice, due to extremely low abundance of positron emission per decay and patient’s intolerability of prolonged scan time, it is very difficult to obtain a scan with decent quality.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Doctor Sean X Yan
Authors: Yan S X, Lim G K
#2792 Post-Transplant Recurrence of Neuroendocrine Tumors
Introduction: Recurrence after liver transplantation (LT) for metastases from NET is observed in 30-50% of cases at 5 years after LT but management is individualized
Conference: 17th Annual ENETS Conference (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#712 A Retrospective Analysis of Safety and Efficacy of Everolimus in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients That Showed Progression after PRRT
Introduction: GEP-NET patients have been treated successfully with SSAs. Upon progression, peptide receptor radiotherapy (PRRT) with 177Lu-octreotate is successful. PRRT is not unlimited. Some patients became refractory after therapy. There is a high medical need. Everolimus (mTOR inhibitor) is a promising therapy for progressive G1/G2 GEP-NETs, with well-established safety. Everolimus has shown efficacy in patients with (non-)PNET (RADIANT-2/-3). However, toxicity data of Everolimus after PRRT is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: drs. Kimberly Kamp
Authors: Kamp K, Feelders R, De Herder W, ...
#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#547 Insulin Autoimmune Syndrome Mimicking Insulinoma: A Challenging Diagnosis
Introduction: Insulin autoimmune syndrome (IAS) is a rare condition characterized by hypoglycemia due to autoantibodies against endogenous insulin. It is correlated, in approximately 50% of cases, to specific drugs intake. Hypoglycemia occurs typically during the late post-prandial period.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#1812 Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study
Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial
Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Florence Marteau
#252 Y90-DOTATATE in Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Survival Following Different Indications for Treatment
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an increasingly used treatment for GEP -NETs but there is limited data on indications, efficacy and survival.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#310 Relationship Between Dose and Molecular Response After Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumors: Preliminary Results
Introduction: PRRNT is an effective therapy option in well-differentiated neuroendocrine tumors. However, there exists no study showing the ability to predict response to PRRNT on a pretherapy Ga-68 SMS-R PET/CT.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof. Dr. med. Richard P Baum
Keywords: dose, molecular, response
#1299 Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma
Introduction: Medullary Thyroid Carcinoma (MTC) is a rare form of thyroid cancer. It represents 5 to 10 % of these cancers. MTC grows from specialized thyroid cells called para-follicular cells, or C-cells that secrete a hormone called calcitonin. Its prognosis is usually good. Recurrences can occur, requiring lifelong surveillance.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team